These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 22715666)

  • 1. [Hepatotropic medicines: current status].
    Ter Arkh; 2012; 84(2):62-8. PubMed ID: 22715666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hepatotropic therapy in treatment of liver injury].
    Sukhanov DS; Okovityĭ SV; Iablonskiĭ PK; Vinogradova TI; Pavlova MV
    Antibiot Khimioter; 2012; 57(5-6):41-52. PubMed ID: 23156043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical efficacy of a succinate-containing infusion drug during pharmacotherapy for hepatic lesions of varying genesis: results of meta-analysis].
    Mazina NK; Mazin PV; Sukhanov DS
    Ter Arkh; 2013; 85(1):56-61. PubMed ID: 23536947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metaanalytic Approach to Evaluate Clinical Effectiveness of Infusion Succinnate-Containing Remaxol in Liver Pathologies of Diverse Genesis].
    Mazina NK; Mazin PV
    Antibiot Khimioter; 2015; 60(11-12):43-9. PubMed ID: 27141647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative effectiveness hepatotropic activity remaxol and Essentiale N in chronic viral hepatitis].
    Pavelkina VF; Ampleeva NP
    Eksp Klin Farmakol; 2014; 77(12):17-21. PubMed ID: 25739188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effectiveness of the hepatoprotective activity of reamberine, remaxol, and ademethionine and risk assessment in their use in patients with respiratory tuberculosis and drug-induced liver injury].
    Sukhanov DS
    Ter Arkh; 2012; 84(11):26-9. PubMed ID: 23252243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hepatoprotective activity of remaxol in patients with chronic hepatic disorders].
    Sologub TV; Goriacheva LG; Sukhanov DS; Romantsov MG; Antonova TV; Iakovlev AA; Radchenko VG; Shul'diakov AA; Rechnik VN; Suzdal'tsev AA; Esaulenko EV; Maksimov SL; Baranova IP
    Klin Med (Mosk); 2010; 88(1):62-6. PubMed ID: 20369616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preclinical study of Reamberin and Remaxol safety].
    Savateeva-Liubimova TN; Lesiovskaia EE; Sivak KV; Stosman KI; Shevchuk MK; Dagaev SG; Savateev AV; Kovalenko AL; Petrov AIu; Sukhanov DS
    Eksp Klin Farmakol; 2010 Nov; 73(11):41-3. PubMed ID: 21254599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Remaxol restores the liver antioxidant protection system in experimental cyclophosphan-induced injury].
    Kovalenko AL; Petrov AIu; Sukhanov DS; Savateeva TN; Romantsov MG
    Eksp Klin Farmakol; 2011; 74(1):32-5. PubMed ID: 21476273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of detoxifying efficacy of remaxol in experimental model of cisplatin-induced toxicosis].
    Bezborodova OA; Nemtsova ER; Aleksandrova LN; Sukhanov DS; Kovalenko AL; Iakubovskaia RI
    Eksp Klin Farmakol; 2011; 74(3):26-31. PubMed ID: 21598634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Controlled clinical trial of a new substance with hepatotropic activity, carried out with an experimental cross-over plan in double-blind conditions].
    Ripamonti C
    Clin Ter; 1972 Jul; 62(1):59-71. PubMed ID: 4561121
    [No Abstract]   [Full Text] [Related]  

  • 13. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of hepatoprotector remaxol infusion on liver function in obstructive jaundice model in rats].
    Smirnova NG; Chefu SG; Kovalenko AL; Vlasov TD
    Eksp Klin Farmakol; 2010 Sep; 73(9):24-7. PubMed ID: 21086649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antioxidant activity of hepatotropic preparations in the treatment of chronic diseases of the liver].
    Loginov AS; Matiushin BN; Sukhareva GV; Tkachev VD
    Ter Arkh; 1988; 60(8):74-7. PubMed ID: 3227482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of remaxol and ademethionine effects on reparative regeneration processes in the liver subjected to surgical intervention].
    Vinogradova TI; Sukhanov DS; Zabolotnykh NV; Kovalenko AL; Vasil'eva SN; Romantsov MG
    Eksp Klin Farmakol; 2011; 74(2):34-8. PubMed ID: 21476284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatoprotective properties of silymarin].
    Matveev AV; Koniaeva EI; Kurchenko VP; Shchekatikhina AS
    Eksp Klin Gastroenterol; 2011; (2):130-5. PubMed ID: 21560654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.
    Temesgen Z; Feinberg JE
    Curr Opin Investig Drugs; 2006 Aug; 7(8):759-65. PubMed ID: 16955688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.